Need help? Text us, a team member replies in minutes+1 (954) 995-1406
Viora Healthcare
Manufactured & Packed in USA
Third-Party Batch Tested
Fast Discreet Shipping
24/7 AI-Powered Support
Physician-Backed Quality
≥99% HPLC Verified
Manufactured & Packed in USA
Third-Party Batch Tested
Fast Discreet Shipping
24/7 AI-Powered Support
Physician-Backed Quality
≥99% HPLC Verified
Research Use Only: All products are for laboratory research only · Not for human or animal use · Researchers must be 21+
Compound ProfileMay 12, 2026·3 min read

Tesamorelin — Research Profile

Tesamorelin is a synthetic analogue of growth hormone–releasing hormone (GHRH), modified to resist enzymatic degradation. Research has explored its action on the somatotropic axis and its effects o...

Tesamorelin — Research Profile

Overview

Tesamorelin is a synthetic analogue of growth hormone–releasing hormone (GHRH), modified to resist enzymatic degradation. Research has explored its action on the somatotropic axis and its effects on body-composition pathway signaling in preclinical and clinical models.

History

GHRH was characterized in the 1980s following the isolation of growth hormone–releasing factors from hypothalamic tissue. Tesamorelin emerged as a stabilized analogue with extended pharmacokinetic profile, becoming one of the more studied GHRH analogues in lipodystrophy and body-composition research.

Tesamorelin Structure

  • CAS #: 218949-48-5
  • Molecular Formula: C₂₂₁H₃₆₆N₇₂O₆₇S
  • Molecular Weight: 5135.86 g/mol
  • PubChem ID: 44147413

Research Findings

Tesamorelin has been studied extensively in clinical and preclinical models concerning the somatotropic axis. Research has documented its action on pulsatile GH release, IGF-1 levels, and visceral adiposity in HIV-associated lipodystrophy populations.

Key Areas of Research

  • Somatotropic: GHRH receptor binding, pulsatile GH
  • Metabolic: visceral adipose tissue modeling
  • Endocrine: IGF-1 axis dynamics
  • Composition: lean/fat mass distribution studies

Tesamorelin has one of the more well-characterized pharmacology profiles among research peptides, with established receptor binding and clinical pharmacokinetics.

References

  1. [1]Falutz J. et al. A placebo-controlled, dose-ranging study of a growth hormone–releasing factor in HIV-infected patients. (2007).
  2. [2]Stanley T. L. et al. Effects of tesamorelin on visceral fat and liver fat in HIV-infected patients. (2011).
  3. [3]Adrian S. et al. The growth-hormone-releasing-hormone receptor in clinical research. (2018).

All references link to the corresponding PubMed record. Citations maintained for transparency — Viora articles are sourced from the published research literature.

For research use only. All compounds referenced in this article are intended strictly for laboratory research and experimentation. Not for human or animal consumption, diagnostic, or therapeutic use.
Compounds covered in this article

Browse related products